 Central Nervous System Stimulants
"Central Nervous System Stimulants" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.
| Descriptor ID |
D000697
|
| MeSH Number(s) |
D27.505.696.282 D27.505.954.427.220
|
| Concept/Terms |
Analeptics- Analeptics
- Analeptic Drugs
- Drugs, Analeptic
- Analeptic Agents
- Agents, Analeptic
|
Below are MeSH descriptors whose meaning is more general than "Central Nervous System Stimulants".
Below are MeSH descriptors whose meaning is more specific than "Central Nervous System Stimulants".
This graph shows the total number of publications written about "Central Nervous System Stimulants" by people in UAMS Profiles by year, and whether "Central Nervous System Stimulants" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2025 | 1 | 0 | 1 | | 2024 | 4 | 2 | 6 | | 2023 | 6 | 0 | 6 | | 2022 | 2 | 0 | 2 | | 2021 | 5 | 1 | 6 | | 2020 | 8 | 1 | 9 | | 2019 | 3 | 2 | 5 | | 2018 | 5 | 2 | 7 | | 2017 | 8 | 2 | 10 | | 2016 | 7 | 0 | 7 | | 2015 | 3 | 1 | 4 | | 2014 | 4 | 3 | 7 | | 2013 | 2 | 3 | 5 | | 2012 | 1 | 0 | 1 | | 2011 | 8 | 0 | 8 | | 2010 | 3 | 0 | 3 | | 2009 | 4 | 2 | 6 | | 2008 | 5 | 1 | 6 | | 2007 | 10 | 2 | 12 | | 2006 | 5 | 1 | 6 | | 2005 | 6 | 6 | 12 | | 2004 | 4 | 2 | 6 | | 2003 | 6 | 1 | 7 | | 2002 | 4 | 2 | 6 | | 2001 | 0 | 1 | 1 | | 2000 | 1 | 0 | 1 | | 1999 | 1 | 2 | 3 | | 1998 | 0 | 2 | 2 | | 1997 | 0 | 1 | 1 | | 1994 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Central Nervous System Stimulants" by people in Profiles over the past ten years.
-
Hiranita T, Hong WC, Sharma A, Lopez JP, Mesangeau C, Whittaker DA, Alsharif W, Kopajtic TA, Jamalapuram S, Avery BA, Tanda G, McCurdy CR, Katz JL. Preclinical Profile of CM699 as a Medication Candidate for Stimulant Use Disorder. ACS Chem Neurosci. 2025 Apr 16; 16(8):1454-1468.
-
Sankhe K, Tumati S, Perin J, Rivet L, Vieira D, Rosenberg PB, Herrmann N, Shade D, Lerner AJ, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey AI, Mintzer J, Lanct?t KL. Correlation between changes in apathy and cognition in Alzheimer's disease associated apathy: Analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). Int Psychogeriatr. 2025 Mar; 37(2):100012.
-
Tumati S, Herrmann N, Perin J, Rosenberg PB, Lerner AJ, Mintzer J, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Shade D, Lanct?t KL. Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2. Int Psychogeriatr. 2024 Dec; 36(12):1232-1244.
-
Tumati S, Herrmann N, Perin J, Rosenberg PB, Lerner AJ, Mintzer J, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Shade D, Lanct?t KL. Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2. Int Psychogeriatr. 2024 12; 36(12):1232-1244.
-
Pro G, Hayes C, Mancino M. Worsening trends in the frequency of methamphetamine and other stimulant use between treatment admission and discharge. Drug Alcohol Depend. 2024 Sep 01; 262:111403.
-
Zeng L, Perin J, Gross AL, Shade D, Lanct?t KL, Lerner AJ, Mintzer JE, Brawman-Mintzer O, Padala PR, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Herrmann N, Rosenberg PB. Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial). Int J Geriatr Psychiatry. 2024 06; 39(6):e6108.
-
Baweja R, Faraone SV, Childress AC, Weiss MD, Loo SK, Wilens TE, Waxmonsky JG. From Consensus Statement to Pills to Pixels: New Innovations in Attention-Deficit/Hyperactivity Disorder Care. J Child Adolesc Psychopharmacol. 2024 05; 34(4):167-182.
-
Fitzgerald LR, Gannon BM, Walther D, Landavazo A, Hiranita T, Blough BE, Baumann MH, Fantegrossi WE. Structure-activity relationships for locomotor stimulant effects and monoamine transporter interactions of substituted amphetamines and cathinones. Neuropharmacology. 2024 Mar 01; 245:109827.
-
Koonce RM, Martin BC. The association between suspected long-COVID and stimulant prescribing in the United States. Psychiatry Res. 2024 Jan; 331:115686.
-
Gannon BM, Fitzgerald LR, Godwin CO, Hughes-Meredith HD, Rice KC, Fantegrossi WE. Effects of ambient temperature on locomotor activity and place conditioning elicited by abused psychostimulants in mice: Role of 3,4-methylenedioxy moiety. Drug Alcohol Depend. 2023 09 01; 250:110917.
-
Pujalte GGA, Narducci DM, Smith MS, King R, Logan K, Callender SS, Liebman CA, Kane SF, Israel MP, Wolf SF, Nuti R, Khodaee M. Athletes With Attention-Deficit/Hyperactivity Disorder: Position Statement of the American Medical Society for Sports Medicine. Clin J Sport Med. 2023 05 01; 33(3):195-208.
-
Lanct?t KL, Chen C, Mah E, Kiss A, Li A, Shade D, Scherer RW, Vieira D, Coulibaly H, Rosenberg PB, Lerner AJ, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Burke WJ, Mintzer J, Herrmann N. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). Int Psychogeriatr. 2023 11; 35(11):664-672.
-
Zhang X, Berridge MS, Apana SM, Slikker W, Paule MG, Talpos J. Discontinuation of methylphenidate after long-term exposure in nonhuman primates. Neurotoxicol Teratol. 2023 May-Jun; 97:107173.
-
Liachenko S, Chelonis J, Paule MG, Li M, Sadovova N, Talpos JC. The effects of long-term methylphenidate administration and withdrawal on progressive ratio responding and T2 MRI in the male rhesus monkey. Neurotoxicol Teratol. 2022 Sep-Oct; 93:107119.
-
Doyle MR, Gannon BM, Mesmin MP, Collins GT. Application of dose-addition analyses to characterize the abuse-related effects of drug mixtures. J Exp Anal Behav. 2022 05; 117(3):442-456.
-
Dwyer MJ, Burrows CA, Drossel C, Raiff BR, Kirby KC. Using the novel functional purchase task to examine prescription stimulant drug effect preferences in college students. Exp Clin Psychopharmacol. 2022 Dec; 30(6):774-786.
-
Mintzer J, Lanct?t KL, Scherer RW, Rosenberg PB, Herrmann N, van Dyck CH, Padala PR, Brawman-Mintzer O, Porsteinsson AP, Lerner AJ, Craft S, Levey AI, Burke W, Perin J, Shade D. Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. JAMA Neurol. 2021 11 01; 78(11):1324-1332.
-
Weiss MD, Surman C, Khullar A, Owens J, He E, Cataldo M, Donnelly G. Effect of a Multilayer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Fixed-Dose, Placebo-Controlled Trial Followed by a 6-Month Open-Label Follow-Up. J Child Adolesc Psychopharmacol. 2021 11; 31(9):623-630.
-
Thompson RG, Oliveto A, Thostenson JD, Wilson MP, McGaugh J, Mancino MJ. Utility of a controlled amphetamine withdrawal paradigm among adults who use methamphetamine: A pilot clinical trial. J Psychopharmacol. 2021 11; 35(11):1420-1430.
-
Weiss MD, Cutler AJ, Kollins SH, Donnelly GAE. Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension. J Child Adolesc Psychopharmacol. 2021 11; 31(9):610-622.
-
Zhang X, Talpos J, Berridge MS, Apana SM, Slikker W, Wang C, Paule MG. MicroPET/CT assessment of neurochemical effects in the brain after long-term methylphenidate treatment in nonhuman primates. Neurotoxicol Teratol. 2021 Sep-Oct; 87:107017.
-
Weiss MD, Surman C, Khullar A, He E, Cataldo M, Donnelly G. Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension. CNS Drugs. 2021 06; 35(6):667-679.
-
Gannon BM, Rice KC, Murnane KS. MDPV "high-responder" rats also self-administer more oxycodone than their "low-responder" counterparts under a fixed ratio schedule of reinforcement. Psychopharmacology (Berl). 2021 Apr; 238(4):1183-1192.
-
Childress AC, Beltran N, Supnet C, Weiss MD. Reviewing the role of emerging therapies in the ADHD armamentarium. Expert Opin Emerg Drugs. 2021 03; 26(1):1-16.
-
Addicott MA, Pearson JM, Schechter JC, Sapyta JJ, Weiss MD, Kollins SH. Attention-deficit/hyperactivity disorder and the explore/exploit trade-off. Neuropsychopharmacology. 2021 02; 46(3):614-621.
-
Berquist MD, McGill MR, Mazur A, Findley DL, Gorman G, Jones CB, Hambuchen MD. Effect of bile duct ligation-induced liver dysfunction on methamphetamine pharmacokinetics in male and female rats. Drug Alcohol Depend. 2020 10 01; 215:108190.
-
Srivastava S, Mennemeier M, Chaudhary JA. A Randomized Placebo Controlled Clinical Trial Demonstrating Safety & Efficacy of EnXtra? in Healthy Adults. J Am Coll Nutr. 2021 Mar-Apr; 40(3):224-236.
-
Horne VE, Bielamowicz K, Nguyen J, Hilsenbeck S, Lindsay H, Sonabend R, Wood AC, Okcu F, Sisley S. Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity. Pediatr Blood Cancer. 2020 07; 67(7):e28379.
-
Mereu M, Hiranita T, Jordan CJ, Chun LE, Lopez JP, Coggiano MA, Quarterman JC, Bi GH, Keighron JD, Xi ZX, Newman AH, Katz JL, Tanda G. Modafinil potentiates cocaine self-administration by a dopamine-independent mechanism: possible involvement of gap junctions. Neuropsychopharmacology. 2020 08; 45(9):1518-1526.
-
Hay CE, Ewing LE, Hambuchen MD, Zintner SM, Small JC, Bolden CT, Fantegrossi WE, Margaritis P, Owens SM, Peterson EC. The Development and Characterization of an scFv-Fc Fusion-Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse. J Pharmacol Exp Ther. 2020 07; 374(1):16-23.
-
Padala PR, Padala KP, Samant RS, James GA. Improvement of neuronal integrity with methylphenidate treatment for apathy in Alzheimer's disease. Int Psychogeriatr. 2020 04; 32(4):539-540.
-
Weiss MD, Childress AC, Donnelly GAE. Efficacy and Safety of PRC-063, Extended-Release Multilayer Methylphenidate in Adults with ADHD Including 6-Month Open-Label Extension. J Atten Disord. 2021 08; 25(10):1417-1428.
-
Berquist MD, Leth-Petersen S, Kristensen JL, Fantegrossi WE. Locomotor effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in mice: psychostimulant effects, stereotypy, and sensitization. Psychopharmacology (Berl). 2020 Feb; 237(2):431-442.
-
Hyatt WS, Berquist MD, Chitre NM, Russell LN, Rice KC, Murnane KS, Fantegrossi WE. Repeated administration of synthetic cathinone 3,4-methylenedioxypyrovalerone persistently increases impulsive choice in rats. Behav Pharmacol. 2019 10; 30(7):555-565.
-
Bullock TA, Berquist MD, Baker LE. Locomotor sensitization in male Sprague-Dawley rats following repeated concurrent treatment with 4-methylmethcathinone and 3,4-methylenedioxymethamphetamine. Behav Pharmacol. 2019 10; 30(7):566-573.
-
Greenhill LL, Swanson JM, Hechtman L, Waxmonsky J, Arnold LE, Molina BSG, Hinshaw SP, Jensen PS, Abikoff HB, Wigal T, Stehli A, Howard A, Hermanussen M, Hanc T. Trajectories of Growth Associated With Long-Term Stimulant Medication in the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2020 08; 59(8):978-989.
-
Addicott MA, Schechter JC, Sapyta JJ, Selig JP, Kollins SH, Weiss MD. Methylphenidate increases willingness to perform effort in adults with ADHD. Pharmacol Biochem Behav. 2019 08; 183:14-21.
-
Garcia-Rill E. Neuroepigenetics of arousal: Gamma oscillations in the pedunculopontine nucleus. J Neurosci Res. 2019 12; 97(12):1515-1520.
-
Compton WM, Han B, Blanco C, Jones CM. Misuse of Immediate-Release Stimulants: Response to Diller. Am J Psychiatry. 2019 01 01; 176(1):77-78.
-
Gannon BM, Mesmin MP, Sulima A, Rice KC, Collins GT. Behavioral economic analysis of the reinforcing effects of "bath salts" mixtures: studies with MDPV, methylone, and caffeine in male Sprague-Dawley rats. Psychopharmacology (Berl). 2019 Mar; 236(3):1031-1041.
-
Timko C, Han X, Woodhead E, Shelley A, Cucciare MA. Polysubstance Use by Stimulant Users: Health Outcomes Over Three Years. J Stud Alcohol Drugs. 2018 09; 79(5):799-807.
-
Weiss M, Childress A, Mattingly G, Nordbrock E, Kupper RJ, Adjei AL. Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial. J Child Adolesc Psychopharmacol. 2018 10; 28(8):521-529.
-
Compton WM, Han B, Blanco C, Johnson K, Jones CM. Prevalence and Correlates of Prescription Stimulant Use, Misuse, Use Disorders, and Motivations for Misuse Among Adults in the United States. Am J Psychiatry. 2018 08 01; 175(8):741-755.
-
Froehlich TE, Becker SP, Nick TG, Brinkman WB, Stein MA, Peugh J, Epstein JN. Sluggish Cognitive Tempo as a Possible Predictor of Methylphenidate Response in Children With ADHD: A Randomized Controlled Trial. J Clin Psychiatry. 2018 Mar/Apr; 79(2).
-
Kangiser MM, Dwoskin LP, Zheng G, Crooks PA, Stairs DJ. Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats. Behav Pharmacol. 2018 02; 29(1):87-97.
-
Scherer RW, Drye L, Mintzer J, Lanct?t K, Rosenberg P, Herrmann N, Padala P, Brawman-Mintzer O, Burke W, Craft S, Lerner AJ, Levey A, Porsteinsson A, van Dyck CH. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. Trials. 2018 Jan 18; 19(1):46.
-
Berquist MD, Fantegrossi WE. Discriminative Stimulus Effects of Psychostimulants. Curr Top Behav Neurosci. 2018; 39:29-49.
-
Weiss MD, Surman CBH, Elbe D. Stimulant 'rapid metabolizers': wrong label, real phenomena. Atten Defic Hyperact Disord. 2018 Jun; 10(2):113-118.
-
Han B, Jones CM, Blanco C, Compton WM. National Trends in and Correlates of Nonmedical Use of Prescription Stimulants, Nonmedical Use Frequency, and Use Disorders. J Clin Psychiatry. 2017 Nov/Dec; 78(9):e1250-e1258.
-
Sweitzer MM, Kollins SH, Kozink RV, Hallyburton M, English J, Addicott MA, Oliver JA, McClernon FJ. ADHD, Smoking Withdrawal, and Inhibitory Control: Results of a Neuroimaging Study with Methylphenidate Challenge. Neuropsychopharmacology. 2018 03; 43(4):851-858.
-
Cheney AM, Newkirk CN, Nekhavhambe VM, Rotondi MB, Hamilton A. Effects of social and spatial contexts on young latinas' methamphetamine use initiation. J Ethn Subst Abuse. 2018 Jan-Mar; 17(1):32-49.
-
Padala PR, Padala KP, Lensing SY, Ramirez D, Monga V, Bopp MM, Roberson PK, Dennis RA, Petty F, Sullivan DH, Burke WJ. Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial. Am J Psychiatry. 2018 02 01; 175(2):159-168.
-
Srivastava S, Mennemeier M, Pimple S. Effect of Alpinia galanga on Mental Alertness and Sustained Attention With or Without Caffeine: A Randomized Placebo-Controlled Study. J Am Coll Nutr. 2017 Nov-Dec; 36(8):631-639.
-
Berquist MD, Thompson NA, Baker LE. Evaluation of training dose in male Sprague-Dawley rats trained to discriminate 4-methylmethcathinone. Psychopharmacology (Berl). 2017 Nov; 234(21):3271-3278.
-
Gannon BM, Russell LN, Modi MS, Rice KC, Fantegrossi WE. Effects of orally self-administered bath salt constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice. Drug Alcohol Depend. 2017 10 01; 179:408-415.
-
Gannon BM, Galindo KI, Mesmin MP, Rice KC, Collins GT. Reinforcing Effects of Binary Mixtures of Common Bath Salt Constituents: Studies with 3,4-Methylenedioxypyrovalerone (MDPV), 3,4-Methylenedioxymethcathinone (methylone), and Caffeine in Rats. Neuropsychopharmacology. 2018 03; 43(4):761-769.
-
Lantz SM, Rosas-Hernandez H, Cuevas E, Robinson B, Rice KC, Fantegrossi WE, Imam SZ, Paule MG, Ali SF. Monoaminergic toxicity induced by cathinone phthalimide: An in vitro study. Neurosci Lett. 2017 Aug 10; 655:76-81.
-
Weisner TS, Murray DW, Jensen PS, Mitchell JT, Swanson JM, Hinshaw SP, Wells K, Hechtman L, Molina BSG, Arnold LE, Sorensen P, Stehli A. Follow-Up of Young Adults With ADHD in the MTA: Design and Methods for Qualitative Interviews. J Atten Disord. 2018 07; 22(9_suppl):10S-20S.
-
George BJ, Li P, Lieberman HR, Pavela G, Brown AW, Fontaine KR, Jeansonne MM, Dutton GR, Idigo AJ, Parman MA, Rubin DB, Allison DB. Randomization to randomization probability: Estimating treatment effects under actual conditions of use. Psychol Methods. 2018 Jun; 23(2):337-350.
-
Katz JL, Hiranita T, Hong WC, Job MO, McCurdy CR. A Role for Sigma Receptors in Stimulant Self-Administration and Addiction. Handb Exp Pharmacol. 2017; 244:177-218.
-
Dougherty DM, Olvera RL, Acheson A, Hill-Kapturczak N, Ryan SR, Mathias CW. Acute effects of methylphenidate on impulsivity and attentional behavior among adolescents comorbid for ADHD and conduct disorder. J Adolesc. 2016 Dec; 53:222-230.
-
Newport DJ, Hostetter AL, Juul SH, Porterfield SM, Knight BT, Stowe ZN. Prenatal Psychostimulant and Antidepressant Exposure and Risk of Hypertensive Disorders of Pregnancy. J Clin Psychiatry. 2016 Nov; 77(11):1538-1545.
-
Reichard EE, Nanaware-Kharade N, Gonzalez GA, Thakkar S, Owens SM, Peterson EC. PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance. Pharm Res. 2016 12; 33(12):2954-2966.
-
Zhang X, Newport GD, Callicott R, Liu S, Thompson J, Berridge MS, Apana SM, Slikker W, Wang C, Paule MG. MicroPET/CT assessment of FDG uptake in brain after long-term methylphenidate treatment in nonhuman primates. Neurotoxicol Teratol. 2016 Jul-Aug; 56:68-74.
-
Hambuchen MD, R?edi-Bettschen D, Gunnell MG, Hendrickson H, Owens SM. Chronic treatment of (+)-methamphetamine-induced locomotor effects in rats using one or a combination of two high affinity anti-methamphetamine monoclonal antibodies. Hum Vaccin Immunother. 2016 09; 12(9):2240-8.
-
Berquist MD, Traxler HK, Mahler AM, Baker LE. Sensitization to the locomotor stimulant effects of "bath salt" constituents, 4-methylmethcathinone (4-MMC) and 3,4-methylenedioxypyrovalerone (MDPV), in male Sprague-Dawley rats. Drug Alcohol Depend. 2016 Jul 01; 164:128-134.
-
Katz JL, Hong WC, Hiranita T, Su TP. A role for sigma receptors in stimulant self-administration and addiction. Behav Pharmacol. 2016 Apr; 27(2-3 Spec Issue):100-15.
-
Gonz?lez CR, Gonz?lez B, Matzkin ME, Mu?iz JA, Cadet JL, Garcia-Rill E, Urbano FJ, Vitullo AD, Bisagno V. Psychostimulant-Induced Testicular Toxicity in Mice: Evidence of Cocaine and Caffeine Effects on the Local Dopaminergic System. PLoS One. 2015; 10(11):e0142713.
-
Moran LV, Masters GA, Pingali S, Cohen BM, Liebson E, Rajarethinam RP, Ongur D. Prescription stimulant use is associated with earlier onset of psychosis. J Psychiatr Res. 2015 Dec; 71:41-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|